<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658836</url>
  </required_header>
  <id_info>
    <org_study_id>TACCSF</org_study_id>
    <nct_id>NCT04658836</nct_id>
  </id_info>
  <brief_title>Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF</brief_title>
  <official_title>Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing surgery of a vestibular schwannoma will be included in the study.&#xD;
      Patients will receive triamcinolone acetonide 24h before surgery. During translabyrinthine&#xD;
      surgery cochlear perilymph, perilymph from the semicircular canal and cerebrospinal fluid&#xD;
      will be taken and analyzed for triamcinolone content. In patients undergoing middle fossa or&#xD;
      retrosigmoid resection only cerebrospinal fluid will be taken and analyzed for triamcinolone&#xD;
      acetonide level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients between 18 and 90 years undergoing surgery of a vestibular schwannoma will be&#xD;
      included in the study. Patients will be offered an application of triamcinolone acetonide&#xD;
      intratympanically on the day before surgery.&#xD;
&#xD;
      During surgery samples will be taken to define how much triamcinolone acetonide enters into&#xD;
      the perilymphatic fluid, the perilymph of the semicircular canals and CSF.&#xD;
&#xD;
      Patients undergoing translabyrinthine surgery will undergoing labyrinthectomy during which&#xD;
      samples of the semicircular canal can be taken. During translabyrinthine surgery nerve&#xD;
      monitoring will be carried out using an intracochlear electrode. Before inserting the&#xD;
      electrode perilymph of the cochlea can be taken. Immediately after opening the dura&#xD;
      cerebrospinal fluid will be taken. Patients undergoing middle fossa or retrosigmoid resection&#xD;
      of the vestibular schwannoma will not undergo sampling of the perilymph. In these patients&#xD;
      cerebrospinal fluid will be taken to determine triamcinolone acetonide levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triamcinolone acetonide level</measure>
    <time_frame>one day</time_frame>
    <description>Drug level</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vestibular Schwannoma</condition>
  <arm_group>
    <arm_group_label>Triamcinolone application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will recieve intratympanic triamcinolone acetonide 24h before vestibular schwannoma surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide 40mg/mL</intervention_name>
    <description>Intratympanic application of triamcinolone acetonide</description>
    <arm_group_label>Triamcinolone application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18 and 90 years undergoing a surgery of the cerebellopontine angle&#xD;
             due to vestibular schwannoma and who are willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years Patients who receive cortison regularly or receive&#xD;
             cortison i.v. or p.o. preoperatively Patients with contraindications against the&#xD;
             administration of Volon√¢A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Arnoldner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Otorhinolaryngology, Head and Neck Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Dahm, MD</last_name>
    <phone>+43/1/40400/33300</phone>
    <email>valerie.dahm@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna (AKH)</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Dahm, MD</last_name>
      <phone>0043/1/40400</phone>
      <phone_ext>33300</phone_ext>
      <email>valerie.dahm@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Arnoldner, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Christoph Arnoldner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

